Ezose Sciences will explore glycans as a possible Parkinson's biomarker

The Michael J. Fox Foundation for Parkinson's Research is giving money to Ezose Sciences in New Jersey to look at the role that glycans play in Parkinson's disease. Neither party is discussing details of the grant, but Ezose will be using its GlycanMap technology to pursue the research. Glycans attach to proteins in the body and affect how they function biochemically, and the idea is that they might be connected to altered protein function as Parkinson's disease and other neurological disorders advance in the body. The hope is that glycans could become a new kind of biomarker that helps, in part, to guide drug development for new drugs for neurological disorders, and also helps better show disease mechanisms. Initial work will focus on glycan profiles in brainstem tissue from rat models of Parkinson's disease and also control rats. Release

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.